(Updated with Deutsche Telekom announcement, Kone warning, BASF divestment)
* Change in futures on the CAC 40 0#FCE index:
* Change in Stoxx 600 0#FXXP index futures:
* Securities that are traded ex-dividend .EX.PA
* Update on European .EUFR markets
PARIS, July 14 (Reuters) – The stocks to watch on Thursday on the Paris Stock Exchange and in Europe:
* ATOS ATOS.PA announced on Wednesday the appointment of Nourdine Bihmane as the group’s managing director, replacing Rodolphe Belmer, whose departure had been announced in mid-June. In addition, S&P Global lowered the group’s credit rating from BBB- to BB, with the new rating remaining with a negative outlook.
➦ Atos appoints Nourdine Bihmane as CEO
* SOCIETE GENERALE SOGN.PA directly and indirectly held a 5.344% stake in Italian group GENERALI GAS.MI as of July 6, shows a stock market notice published on Wednesday.
* SANOFI SASY.PA has published positive results from a phase III trial of its Dupixent in the treatment of eosinophilic esophagitis in children aged one to 11 years. (The press release: )
* ERICSSON ERICb.ST published quarterly adjusted operating profit (Ebit) up but below expectations, as higher component prices and logistics costs reduced its margin.
* SWATCH GROUP UHR.S – The Swiss watchmaking group reaffirmed on Thursday that it expects double-digit sales growth this year after publishing higher half-year results.
* DEUTSCHE TELEKOM DTEGn.DE has announced that it has completed the sale of 51% of the capital of its mobile telephony relay subsidiary to a consortium combining Brookfield BAMa.TO and DigitalBridge, based on an enterprise value of 17.5 Billions of Euro’s.
* KONE KNEBV.HE – The elevator maker lowered its forecast for full-year revenue and profit due to weaker-than-expected sales in the second quarter and a deteriorating outlook for the Chinese market.
* SEB SEBa.ST – The Swedish bank posted a quarterly profit that was down but better than expected, as rising interest rates and improving business demand offset the impact of turmoil in financial markets.
* BASF BASFn.DE announced on Thursday the sale of its testosterone deficiency treatment Nebido to the Grünenthal laboratory for an amount which could reach 500 million euros.
* HUGO BOSS BOSSn.DE on Wednesday raised its forecast for annual results, highlighting an acceleration in commercial momentum in the second quarter. The title gained 1.9% in the first trading before the stock market.
THE FRANCE & INTERNATIONAL 7-DAY AGENDA:
(Written by Claude Chendjou and Marc Angrand, edited by Kate Entringer)